Form 4: Compass Therapeutics CEO Boosts Equity Holdings

Compass Therapeutics CEO Thomas J. Schuetz acquired 250,000 restricted stock units and 2,000,000 stock options, signaling increased equity alignment.

Summary

• Thomas J. Schuetz, CEO and Director of Compass Therapeutics, Inc. (CMPX), reported the acquisition of equity securities.
• On January 2, 2026, Mr. Schuetz was granted 250,000 Restricted Stock Units (RSUs) at a price of $5.17 per unit.
• Each RSU represents a contingent right to receive one share of common stock, subject to service-based vesting conditions.
• These RSUs will vest in four equal annual installments, with the first vesting scheduled for January 2, 2027.
• Additionally, on January 2, 2026, Mr. Schuetz was granted 2,000,000 stock options with an exercise price of $5.17 per share.
• The stock options will vest over 48 substantially equal monthly installments, commencing on February 2, 2026, and expire on January 2, 2036.
• Following these transactions, Mr. Schuetz beneficially owns 6,686,800 shares of Common Stock and 2,000,000 stock options.
• Previous RSU grants include 250,000 on February 8, 2023 (first vested Feb 8, 2024) and 478,125 on January 9, 2024 (first vested Jan 9, 2025).

Sentiment

Score: 7

Explanation: The grant of significant equity awards to the CEO, including RSUs and stock options, is generally viewed positively as it aligns management's long-term interests with those of shareholders. The vesting schedules reinforce this long-term commitment.

Positives

• CEO Thomas J. Schuetz significantly increased his equity holdings in Compass Therapeutics, Inc. through new RSU and stock option grants, aligning his interests with shareholders.
• The acquisition of 250,000 RSUs and 2,000,000 stock options at a price of $5.17 per share demonstrates a long-term commitment to the company's performance.
• The multi-year vesting schedules for both RSUs (four equal annual installments) and stock options (48 monthly installments) reinforce the CEO's sustained dedication to the company's future.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CEO's interests with long-term company performance and value creation.
• Employees: May signal confidence in the company's future direction and stability, potentially boosting morale and retention.

Next Steps

• Continued vesting of 250,000 RSUs granted on January 2, 2026, with the first installment on January 2, 2027.
• Continued vesting of 2,000,000 stock options over 48 monthly installments starting February 2, 2026.
• Continued vesting of previously granted RSUs from February 8, 2023, and January 9, 2024.

Key Dates

Recommendation

The significant equity grants to the CEO, comprising 250,000 Restricted Stock Units and 2,000,000 stock options, demonstrate a strong alignment of management's long-term interests with shareholder value creation. While these are grants and not open market purchases, the substantial increase in the CEO's beneficial ownership, coupled with multi-year vesting schedules, suggests confidence in the company's future prospects. This action reinforces a 'hold' recommendation, as it indicates stability in leadership commitment without providing new fundamental performance data to warrant a stronger buy or sell signal.

Keywords

Compass Therapeutics, CMPX, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, CEO, Equity Grant, Executive Compensation, Beneficial Ownership